Delisting riskEarnings are out
NewGenIVF Group (NIVF)
Provides fertility treatment and referral services in Thailand, Cambodia, and Kyrgyzstan.
$1.23
Pre-market+0.03 (+2.50%)
At close$1.20(−9.77%)
In millions of USD, except per-share figures
| In millions | Q1 FY22Mar 2022 | Q2 FY22Jun 2022 | Q3 FY22Sep 2022 | Q4 FY22Dec 2022 | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | −1 | −3 | −5 |
| 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 19 | −3 | |
| Interest income | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −1 | −1 | 0 | −1 | 0 | 0 | −1 | −19 | 2 |
| Income before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 17 | −8 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | −8 |
| Net income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | −8 |
| EPS, basic | −$82.16 | −$9.58 | $69.53 | $158.37 | $83.61 | $137.18 | $204.24 | $287.85 | −$11.76 | −$41.37 | $257.40 | −$117.36 |
| EPS, diluted | −$82.16 | −$9.58 | $69.53 | $158.37 | $83.61 | $137.18 | $204.24 | $287.85 | −$11.76 | −$41.37 | $257.40 | −$117.36 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | −7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | −7 |
